

Luxembourg, 10 October 2023

Public

Environmental and Social Data Sheet¹

Overview

Project Name:	BIOHOPE (IEU TI)
Project Number:	20230332
Country:	Spain
Project Description:	Company dedicated to the development of precision medicine in-vitro diagnostic tools for chronic inflammatory conditions
EIA required:	no
Invest EU sustainability proofing required	yes
Project included in Carbon Footprint Exercise ² :	no

Environmental and Social Assessment

Environmental Assessment

The Promoter is a medical technology company focused on development of in-vitro diagnostic (IVD) tests for predicting patients' response to drugs used in various conditions, including the prevention of renal transplant rejection and potentially the treatment of other immune-based conditions.

The project concerns investments in research and development activities carried out by the Promoter and its partners in existing facilities without changing their already authorised scope. The research and development activities of the project do not fall under either Annex I or Annex II of the EU Directive 2011/92/EU amended by Directive 2014/52/EU.

Climate Assessment

The project has been assessed for Paris alignment in line with the EIB Climate Bank Roadmap requirements: the activities are aligned as they do not impact climate change and are considered not be sensitive to climate hazards.

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high emitting sector and is not considered as a highly vulnerable counterpart.

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary.

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, 10 October 2023

Social Assessment

The company ensures compliance with health and safety requirements in line with the relevant EU directives and guidelines for workplaces.

Other Environmental and Social Aspects

If successful, the project will contribute to the creation and deployment of superior diagnostics to predict the most effective immunosuppressive drugs to prevent kidney transplant rejection and to treat immune-based diseases. As such, this project will potentially improve outcomes of kidney transplantation and other immune-based conditions.

Through the R&D activities and investments, the project will aid the Promoter to create additional highly skilled RDI jobs, while positively contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The Promoter has effective E&S policies and operating procedures in place, which are in line with industry standards.

The project concerns investments in research and development for which no significant residual impact on the environment is expected.

Sustainability proofing conclusion: the project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information and based on the review of the likely significant ECS risks and impacts and the mitigation measures and management systems in place, the project is deemed to have low residual ECS risks and impacts. No further sustainability proofing is required.

Considering the above, taking into consideration the Environmental, Social and Climate impacts of this RDI project, including the capacity of the Promoter and the overall net positive social impact, this project is deemed acceptable for the Bank's financing under environmental and social terms.